NCT01723072 - Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2013

Primary Completion Date

May 9, 2014

Study Completion Date

May 9, 2014

Conditions

Chronic Spontaneous UrticariaAngioedema

Interventions

BIOLOGICAL

Omalizumab

Humanized monoclonal antibody against human IgE

DRUG

Placebo

Placebo to omalizumab

Trial Locations (25)

13353

Novartis Investigative Site, Berlin

24105

Novartis Investigative Site, Kiel

26133

Novartis Investigative Site, Oldenburg

30625

Novartis Investigative Site, Hanover

40225

Novartis Investigative Site, Düsseldorf

44791

Novartis Investigative Site, Bochum

45147

Novartis Investigative Site, Essen

50937

Novartis Investigative Site, Cologne

52074

Novartis Investigative Site, Aachen

53105

Novartis Investigative Site, Bonn

55131

Novartis Investigative Site, Mainz

56242

Novartis Investigative Site, Selters

64283

Novartis Investigative Site, Darmstadt

65199

Novartis Investigative Site, Wiesbaden

66421

Novartis Investigative Site, Homburg

68305

Novartis Investigative Site, Mannheim

79106

Novartis Investigative Site, Freiburg im Breisgau

81377

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

86179

Novartis Investigative Site, Augsburg

91054

Novartis Investigative Site, Erlangen

93053

Novartis Investigative Site, Regensburg

01307

Novartis Investigative Site, Dresden

07548

Novartis Investigative Site, Gera

06120

Novartis Investigative Site, Halle